Jiang Lindi

Lindi (Jiangsu) Biotechnology is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for the treatment of solid tumors. Founded by Dr. Jiang Lindi, a veteran in the CAR-T field, the company leverages its proprietary technology platforms to engineer CAR-T and TCR-T cells with enhanced efficacy and persistence in the immunosuppressive tumor microenvironment. Its lead candidate, LD01, is a CAR-T therapy targeting Glypican-3 (GPC3) currently being evaluated in clinical trials for advanced hepatocellular carcinoma. The company's research focuses on overcoming the physical and immunological barriers of solid tumors to improve patient outcomes. Lindi Biotech is headquartered in the Suzhou Industrial Park, China, and is actively expanding its pipeline of next-generation immunotherapies.